Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 23 Jan 2018 |
| Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S. | 23 Jan 2018 |
| Zealand Pharma strengthens its Management by appointing Ivan Møller as SVP, Technical Development & Operations | 19 Jan 2018 |
| Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018 | 19 Jan 2018 |
| Zealand Pharma major shareholder announcement: Royce & Associates, LLC, U.S. | 15 Jan 2018 |
| Zealand Pharma major shareholder announcement: Wellington Management Group LLP, U.S. | 3 Jan 2018 |